2025 Expert Consensus on the Design of Interventional Clinical Studies for Malignant Pleural Effusion (2025 Edition)

Expert Consensus on the Design of an Interventional Clinical Study of Malignant Pleural Effusion

2025-07-10

Learn more

CACA China Integrated Diagnosis and Treatment Guidelines for Peritoneal Tumors - 2025 Edition

Peritoneal tumors are mainly classified as primary and secondary. Primary tumors originate from the peritoneum; common types include primary peritoneal cancer (Müllerian-type epithelial tumors, mainly serous carcinoma) and malignant peritoneal mesothelioma (MPM). Secondary tumors include various metastatic cancers, peritoneal sarcomatosis (PS), pseudomyxoma peritonei (PMP), and gliomatosis. Clinically, metastatic and epithelial malignant peritoneal tumors are more common, while primary and mesenchymal tumors are relatively rare and considered rare diseases.

2025-07-10

Learn more

Chinese Expert Consensus on the Diagnosis and Treatment of Colorectal Cancer Peritoneal Metastasis (2025 Edition)

Colorectal cancer is one of the most common malignant tumors in China, ranking second and fourth in incidence and mortality rates among all malignant tumors, respectively. Metastasis and recurrence are the main causes of death in patients with colorectal cancer. The peritoneum is a common site of colorectal cancer metastasis, second only to liver and lung metastasis, but its prognosis is far worse than that of liver and lung metastasis.

2025-07-10

Learn more

【New Law】Application and Key Points of Thoracic Thermal Perfusion Chemotherapy in Thoracic Treatment

Malignant pleural effusions (MPEs) are mainly seen in patients with advanced lung cancer (37.5%), breast cancer (16.8%), lymphoma (11.5%), genitourinary malignancies (9.4%), and gastrointestinal malignancies (6.9%); the median overall survival time for patients with MPEs and pleural metastases is 3-4 months.

2025-07-10

Learn more

Chinese Expert Consensus on the Diagnosis and Treatment of Platinum-Resistant Recurrent Ovarian Cancer (2025 Edition)

Among gynecological malignancies, ovarian cancer has the most grim prognosis, primarily due to its high recurrence risk after treatment. Multiple recurrences lead to increased drug resistance. Recurrent ovarian cancer is classified into platinum-sensitive and platinum-resistant types, and treatment strategies depend on the patient's sensitivity to platinum-based chemotherapy. For patients with platinum-sensitive recurrent ovarian cancer, the use of platinum-based chemotherapy combined with targeted therapy (such as PARP inhibitors or bevacizumab) has been shown to prolong survival.

2025-07-10

Learn more

Science Translational Medicine research paper: Hyperthermia reshapes the tumor microenvironment and proposes a new strategy for combined treatment of ovarian cancer

Hyperthermic intraperitoneal chemotherapy (HIPEC) has been used to treat gastric cancer, but its efficacy in patients with peritoneal metastasis of ovarian cancer remains unclear, hindering the development of rational combination therapies based on hyperthermia (HT).

2025-07-09

Learn more

Retrospective analysis on the safety of 5,759 times of bedside hyperthermic intra-peritoneal or intra-pleural chemotherapy (HIPEC)

The current study was designed to analyze safety of the bedside hyperthermic intra-pleural or intra-peritoneal chemotherapy (HIPEC) from September 2007 to July 2015. Total of 5,759 times of bedside HIPEC in 985 cases of malignant pleural or peritoneal carcinomatosis were analyzed.

2025-07-08

Learn more

Thermal Chemotherapy for Tumors - Current Status and Prospects

Drug treatment for tumors, commonly known as chemotherapy, is currently one of the main methods for treating tumors. With the increasing incidence of malignant tumors, research in related fields is very active worldwide. The emergence of new drugs and the standardization and improvement of chemotherapy regimens have led to a certain degree of improvement in the survival rate and survival time of cancer patients.

2022-08-26

Learn more

Clinical Analysis of Malignant Chest and Abdominal Cavity Hyperthermic Intraperitoneal Chemotherapy

Malignant pleural and abdominal effusion is one of the common clinical manifestations and serious complications of malignant tumors. Any malignant tumor can cause malignant pleural and abdominal effusion when it invades the thoracic or abdominal cavity. The treatment of malignant pleural and abdominal effusion can be divided into systemic and local treatment methods. For malignant tumors that are sensitive or relatively sensitive to chemotherapy, systemic chemotherapy can lead to malignant pleural effusion.

2022-08-26

Learn more
< 12 >